NCT05688618 Effect of the Administration of a Symbiotic (E. Faecium and Agave Inulin) on Mild Cognitive Impairment in Older Adults
| NCT ID | NCT05688618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anahuac University |
| Condition | Cognitive Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2022-11-16 |
| Primary Completion | 2024-05-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2022-11-16 with a primary completion date of 2024-05-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cognitive impairment is one of the fastest growing diseases in the last decades, given the significant increase in senior citizen population in Mexico and the world. Several studies have discussed the gut-microbiota-brain axis. It has been demonstrated that a balanced gut microbiota, prevents an increase in pro-inflammatory cytokines that affect specific brain areas; having an important impact at the cortical level of the hippocampus which translates to diminished cognitive function and the start of cognitive impairment symptoms. After multiple studies on the effect of the administration of symbiotics in animal models in cognition and memory, there have been positive results, observing improvement in cognition and decrement in inflammatory cytokines at hippocampus level.
Eligibility Criteria
Inclusion Criteria: * Patients with mild cognitive impairment * Patients who sign the informed consent Exclusion Criteria: * Patients who do not have mild cognitive impairment * Patients with advanced cognitive impairment such as Alzheimers disease * Patients with comorbidities that influence the cognitive functions such as diabetes mellitus, cerebral ischemia or previous brain trauma * Patients who do not sign the informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05688618 clinical trial?
This trial is open to participants of all sexes, aged 70 Years or older, up to 85 Years, studying Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05688618 currently recruiting?
Yes, NCT05688618 is actively recruiting participants. Contact the research team at jose.ibarra@anahuac.mx for enrollment information.
Where is the NCT05688618 trial being conducted?
This trial is being conducted at Mexico City, Mexico.
Who is sponsoring the NCT05688618 clinical trial?
NCT05688618 is sponsored by Anahuac University. The trial plans to enroll 48 participants.